聯(lián)系方式
個(gè)人簡(jiǎn)介
1980-1985年：佳木斯醫學(xué)院，醫學(xué)學(xué)士
1987-1990年：哈爾濱醫科大學(xué)，醫學(xué)碩士
1994-1997年：哈爾濱醫科大學(xué)，遺傳學(xué)博士
1985-1987年：佳木斯醫學(xué)院，微生物與免疫教研室，助教
1990-1994年：哈爾濱醫科大學(xué)，生物學(xué)教研室，講師
1997-1999年：哈爾濱醫科大學(xué)，預防醫學(xué)博士后流動(dòng)站，博士后
1999-2004年：哈爾濱醫科大學(xué)，遺傳學(xué)研究室，教授
2001-2003年：哈佛大學(xué)醫學(xué)院，分子病理學(xué)實(shí)驗室，訪(fǎng)問(wèn)學(xué)者
2004年-至今：哈爾濱工業(yè)大學(xué)，生命科學(xué)與技術(shù)學(xué)院，教授
Personal Profile
1980 - 1985 Jiamusi Medical College, Bachelor of Medicine
1987 - 1990 Harbin Medical University, Master of Medicine
1994 - 1997 Harbin Medical University, Doctor of Genetics
1985 - 1987 Department of Microbiology and Immunology, Jiamusi Medical College, Teaching assistant
1990 - 1994 Harbin Medical University, Department of Biology, Lecturer
1997 - 1999 Harbin Medical University, Postdoctoral research station of Preventive Medicine
1999 - 2004 Genetics Laboratory, Harbin Medical University, Professor
2001 - 2003 Harvard Medical School, Molecular Pathology Laboratory, Visiting Scholar
2004 - present Harbin Institute of Technology, School of Life Science and Technology, Professor
研究方向和領(lǐng)域
腫瘤細胞生物學(xué)
Tumor Cell Biology
腫瘤代謝組學(xué)
Tumor Metabolomics
腫瘤糖生物學(xué)
Tumor Glycobiology
主要研究方向
腫瘤相關(guān)基因表達與功能研究
Study on the expression and function of tumor related genes
腫瘤分子標志物
Tumor molecular markers
分子診斷
Molecular diagnosis
研究?jì)热?/span>
主要開(kāi)展腫瘤細胞生物學(xué)、重大疾病分子診斷、癌癥代謝組和糖組學(xué)研究，實(shí)現生物醫學(xué)技術(shù)轉化。
1. 發(fā)現MARVELD1的多功能特征：高度保守，影響細胞運動(dòng)遷移能力，參與個(gè)體多器官分化發(fā)育，影響內胚層上皮細胞的自穩狀態(tài)，作為候選抑癌基因影響細胞表面的超微結構，抑制腫瘤細胞的遷移運動(dòng)，并調控DNA損傷與修復功能。
2. 開(kāi)展癌癥代謝重編程研究：研究肝癌、胰腺癌和結腸癌的血清、組織和細胞中小分子代謝物特征，篩選高特異性的腫瘤標志物；構建原發(fā)性肝癌脂類(lèi)代謝失衡的分子網(wǎng)絡(luò )；揭示與胰腺癌密切相關(guān)的花生四烯酸代謝關(guān)鍵通路的作用機制。
3. 應對新型冠狀病毒疫情，推進(jìn)醫工交叉，研發(fā)核酸檢測一體化設備與試劑，快速實(shí)現技術(shù)轉化。
Research Interests
Professor Li Yu's research focuses on tumor cell biology, molecular diagnosis of diseases, cancer metabolomics, glycomic and the transformation of biomedical technology.
1. Professor Li Yu's research team found that the multifunctional characteristics of MARVELD1 were highly conserved, affecting cell mobility and migration, participating in the differentiation and development of multiple organs, affecting the self-stable state of endodermal epithelial cells, affecting the ultrastructure of cell surface as a candidate tumor inhibitor gene, inhibiting the migration and movement of tumor cells, and regulating DNA damage and repair function.
2. The research team focuses on cancer metabolic reprogramming: To study the characteristics of small molecular metabolites in serum, tissues and cells of liver cancer, pancreatic cancer and colon cancer, and to screen high specific tumor markers; To construct the molecular network of lipid metabolism imbalance in primary liver cancer; To reveal the mechanism of the key pathway of arachidonic acid metabolism which is closely related to pancreatic cancer.
3. In response to the Novel coronavirus outbreak, we have promoted the integration of medical and industrial research and development, and developed integrated nucleic acid testing equipment and reagents, so as to achieve rapid technology transformation.
研究成果
近五年內承擔或主持重要項目6項，其中包括：中國工程院防疫應急重大儀器研究項目、黑龍江省“頭雁”計劃、國家自然科學(xué)基金面上項目以及深圳市科創(chuàng )委學(xué)科布局項目、深圳市科創(chuàng )委技術(shù)攻關(guān)項目等。
主要代表性科研論文：
1. Xiaoqing Zhang, Peng Dou, Muhammad Luqman Akhtar, Fei Liu, Xibo Hu, Lijun Yang, Depeng Yang, Xiaohan Zhang, Yiqun Li, Shupei Qiao, Kai Li, Ran Tang, Chao Zhan, Yue Ma , Qixiang Cheng, Yan Bai, Fang Han, Huan Nie*, Yu Li*.NEU4 inhibits motility of HCC cells by cleaving sialic acids on CD44.Oncogene, doi: 10.1038/s41388-021-01955-7. 2021.
2. Depeng Yang, Lijun Yang, Jialing Cai, XiboHu, Huaxin Li, Xiaoqing Zhang, Xiaohan Zhang, Xinghe Chen, Haiyang Dong, Huan Nie*, Yu Li*. A sweet spot for macrophages: Focusing on polarization. Pharmacol Res. 167:105576. doi: 10.1016/j.phrs.2021.105576. 2021.
3. Chunbo Wang, Depeng Yang, Xiaoqing Zhang, Xiaohan Zhang, Lijun Yang, Pingping Wang, Wenyang Zhou, Huaxin Li, Yiqun Li, Huan Nie, Yu Li*. Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy.Front Genet. 23; 11:298. doi: 10.3389/fgene.00298. eCollection 2020.
4. Xiaohan Zhang, Xiuyun Shi, Xin Lu, Yiqun Li, Chao Zhan, Muhammad Luqman Akhtar, Lijun Yang, Yunfan Bai, Jianxiang Zhao, Yu Wang, Yuanfei Yao, Yu Li*, and Huan Nie. Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples. J Cancer. 11(16): 4641- 4651, 2020.
5. Zongjun Liu#, Tuo Li, Fang Han, You Wang,* Yang Gan,* Junhui Shi, Tianran Wang, Muhammad Luqman Akhtar, and Yu Li*.A Cascade-Reaction Enabled Synergistic Cancer Starvation/ROS-mediated /chemotherapy with Enzyme Modified Fe-based MOF. Biomater Sci,7(9): 3683-3692, 2019.
6. Chunbin Zhang, Fang Han, Ming Shi, Haoxiu Sun, Yiqun Li, Yanpeng Ci, Yuanfei Yao, Peng Dou, Muhammad luqman Akhtar, Huan Nie, Jie He, Li Y*. MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system. Mol Carcinog, 08;58(8):1410-1426, 2019.
7. Xin Lu, Xiaohan Zhang, Yongjian Zhang, Kun Zhang, Chao Zhan, Xiuyun Shi, Yiqun Li, Jianxiang Zhao, Yunfan Bai, Yu Wang, Huan Nie*, Yu Li*. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2. Mol Carcinog, 58(5):749-759. doi: 10.1002/mc.22967.2019.
8. Yanpeng Ci, Xiaoning Li, Maorong Chen, Jiateng Zhong, Brian J. North, Hiroyuki Inuzuka, Xi He, Yu Li* & Jianping Guo* & Xiangpeng Dai*. SCF E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation. Protein Cell,9(10):879-889, 2018.
9. Weizhe Liu, Fang Han, Shuai Qu, Yuanfei Yao, Jianxiang Zhao, Muhammad Luqman Akhtar, Yanpeng Ci, Hao Zhang, Hongfei Li, Yufang Zhao, Lei Yue, Yao Zhang, Changlin Wang*&Yu Li*. MARVELD1 depletion leads to dysfunction of motor and cognition via regulating glia-dependent neuronal migration during brain development. Cell Death & Disease, 9: 999, 2018.
10. Chen Y, Zhang H, Han F, Yue L, Qiao C, Zhang Y, Dou P, Liu W, Li Y*. The depletion of MARVELD1 leads to murine placenta accreta via integrin β4-dependent trophoblast cell invasion. J Cell Physiol, 233(3): 2257-2269, 2018.
11. Yao Y, Shi M, Liu S, Li Y, Guo K, Ci Y, Liu W, Li Y*. MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in non-small cell lung cancer. Mol Carcinog.55(11):1714-1727. doi: 10.1002/mc.22421. 2016.
主要發(fā)明專(zhuān)利：
1. 人源調控細胞死亡的C1ORF109重組蛋白及其制備方法與應用。授權編號：2018111449544。發(fā)明人排序：第一位。
2. 一種胰腺導管腺癌標志物及其篩選方法。授權編號：2018110521959。發(fā)明人排序：第二位。
教師個(gè)人主頁(yè)鏈接
http://homepage.hit.edu.cn/liyu
